Why the future of marijuana legalization remains hazy despite high public support 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CDC Monitors 41 Americans After Andes Hantavirus Outbreak on Luxury Cruise Ship 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Many companies are already undergoing trials for a possible cure to the ongoing COVID-19 pandemic. Aside from the developments made by Pfizer and Moderna in developing their respective vaccines, another pharmaceutical company has made progress.
UK pharmaceutical firm AstraZeneca has developed a COVID-19 antibody cocktail that can potentially protect the person from infection for up to 12 months. The drug, known as AZD7442, makes use of a different process in helping the body fight the virus compared to a regular vaccine. Late-stage trials of the drug are already underway and the firm has started recruiting international clinical trials involving 5,000 from both Europe and the United States.
AZD7442 relies on the prophylactic process which involves introducing new antibodies into the body to fight the disease instead of triggering the body to create them. The drug acts with monoclonal antibodies that mimic the body’s natural antibodies and this process has already been used to treat cancer patients. This will especially be beneficial for those with weak immune systems compared to simply being vaccines as their bodies have already been compromised from creating new antibodies. The trials began over the weekend in the UK, involving 1,000 participants in nine sites.
The firm announced that this antibody cocktail can potentially treat patients or be taken as a preventative medication especially to healthcare workers at the front lines. “These have been engineered specifically to have what we call a long half-life, so we think they can confer protection for at least six, but more likely closer to 12 months,” said the company’s executive vice president of biopharmaceuticals research and development Mene Pangalos.
As the world waits for vaccines and a cure for COVID-19, people are highly advised to adhere to public health and safety guidelines to slow the spread of the coronavirus. Video streaming platform YouTube recently clamped down on the right-wing media organization OANN from posting videos and live streaming for a week, after the organization shared a fake cure for the disease.
Aside from restricting uploads, YouTube has also demonetized the channel, citing that the OANN has repeatedly violated its misinformation guidelines especially related to COVID-19.
